

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
07 May 2020 (07.05.2020)



(10) International Publication Number
WO 2020/092019 A1

(51) International Patent Classification:
C07D 471/04 (2006.01) *A61K 31/437* (2006.01)
A61P 27/02 (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/US2019/056947

Published:
— with international search report (Art. 21(3))

(22) International Filing Date:
18 October 2019 (18.10.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/751,967 29 October 2018 (29.10.2018) US

(71) Applicant: **THERAVANCE BIOPHARMA R&D IP, LLC** [US/US]; 901 Gateway Boulevard, South San Francisco, California 94080 (US).


(72) Inventors: **FATHEREE, Paul R.**; 901 Gateway Blvd., South San Francisco, California 94080 (US). **JIANG, Lan**; 901 Gateway Blvd., South San Francisco, California 94080 (US).

(74) Agent: **HAGENAH, Jeffrey A.** et al.; Theravance Biopharma US, Inc., 901 Gateway Boulevard, South San Francisco, California 94080 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: 2-AZABICYCLO HEXANE COMPOUND AS JAK INHIBITOR



(57) Abstract: The invention provides a compound of formula 1 or a pharmaceutically-acceptable salt thereof, that is useful as a JAK inhibitor. The invention also provides pharmaceutical compositions comprising the compound, methods of using the compound to treat diseases amenable to a JAK inhibitor, and processes useful for preparing the compound.

WO 2020/092019 A1